Andrew Muir
Andrew joined Midven in 2004. He is a Director of the Company and Investment Director of the Rainbow Seed Fund, focusing on the life sciences.
The Rainbow Seed Fund is a £8.5m venture capital fund for the principal Public Sector Research Establishments (PSREs), including CCLRC, BBSRC, dstl, NERC, UKAEA, PPARC, VLA, CSL and HPA. The fund, which is managed by Midven Ltd, has committed over £2m of investment into 11 spin out companies. Midven also manages the £25m Advantage Growth Fund, a regional fund investing in high growth West-Midlands based companies.
Andrew was previously an investment manager at the National Endowment for Science Technology & the Arts (NESTA), the single largest source of seed capital in the UK, and prior to that he was Vice President of Technology for the private-equity backed medical device company Sterilox Technologies, and Materials Research manager for Biocompatibles plc.
He is currently non exec Chairman of Chameleon BioSurfaces, a spin-out from the John Innes Centre, and a Director of Warwick Effect Polymers, a spin-out from Warwick University. He has a degree and a PhD in Chemistry from the University of Oxford.
